Patents by Inventor Peter A. Crooks

Peter A. Crooks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7045538
    Abstract: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: May 16, 2006
    Assignee: Targacept, Inc.
    Inventors: William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif
  • Publication number: 20060009468
    Abstract: A method for the treatment of cancer that includes in vivo delivering a sensitizer to a patient that has cancer; and exposing the patient to ionizing radiation, hyperthermia or an anticancer chemotherapeutic agent, or combinations of these agents. The sensitizer may be a structural analog of L-arginine, such as L-Canavanine or an ester prodrug of structural analogs of L-arginine, such as an ester of L-Canavanine. The chemotherapeutic agent may include DNA-interactive agents such as alkylating agents, e.g. cisplatin, cyclophosphamide, altretamine; DNA strand-breakage agents, such as bleomycin; intercalating topoisomerase II inhibitors, eg., dactinomycin and doxorubicin); nonintercalating topoisomerase II inhibitors such as, etoposide and teniposide; and the DNA minor groove binder plicamydin, for example.
    Type: Application
    Filed: July 7, 2005
    Publication date: January 12, 2006
    Inventors: Peter Crooks, Robert Alonso
  • Patent number: 6979695
    Abstract: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: December 27, 2005
    Assignee: Targacept, Inc.
    Inventors: William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif
  • Publication number: 20050282846
    Abstract: Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.
    Type: Application
    Filed: July 14, 2005
    Publication date: December 22, 2005
    Inventors: Willian Caldwell, Gary Dull, Balwinder Bhatti, Srishailkumar Hadimani, Haeil Park, Jared Wagner, Peter Crooks
  • Publication number: 20050272716
    Abstract: The present invention provides compounds of the formula (I) wherein: X1, X2 and X3 are heteroatoms; R4, R5, P6, R7, R8, R9 and R10 are independently selected from H, halo, —OH, —NO2, —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR1—, —C(O)NR1NR2—, —C(O)O—, —OC(O)—, —NR1CO2—, —O—, —NR1C(O)NR2—, —OC(O)NR1—, —NR1NR2—, —NR1C(O)—, —S—, —SO—, —SO2—, —NR1—, —SO2NR1—, —NR1R2, or —NR1SO2—, wherein R1 and R2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR1R2, R1 and R2 optionally together with the nitrogen atom form an optionally substituted 5-12 m
    Type: Application
    Filed: January 7, 2005
    Publication date: December 8, 2005
    Inventors: Peter Crooks, Craig Jordan, Xiaochen Wei
  • Publication number: 20050261334
    Abstract: N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter.
    Type: Application
    Filed: January 3, 2005
    Publication date: November 24, 2005
    Inventors: Peter Crooks, Linda Dwoskin, Joshua Ayers, Vladimir Grinevich, Sangeetha Sumithran
  • Patent number: 6943177
    Abstract: Cis-2,6-disubstituted piperdine analogs, or lobeline analogs, having the general formula: are used to treat diseases of the central nervous system, drug abuse and withdrawal therefrom as well as to treating eating disorders.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: September 13, 2005
    Assignee: University of Kentucky Research Foundation
    Inventors: Linda P. Dwoskin, Peter A. Crooks, Marlon D. Jones
  • Publication number: 20050154002
    Abstract: The invention is directed to forming duplex prodrugs that provide significant increase in the transdermal flux of drugs across human skin. The prodrugs are prepared by reacting a drug that can form an ester moiety with phosgene to form a carbonate. The drug can be an opiate or an opiate antagonist. When in contact with human skin, the duplex drug is biotransformed by enzymes or by hydrolysis into two drug molecules.
    Type: Application
    Filed: July 23, 2004
    Publication date: July 14, 2005
    Inventors: Peter Crooks, Mohamed Hamad, Audra Stinchcomb
  • Publication number: 20050148611
    Abstract: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.
    Type: Application
    Filed: October 22, 2004
    Publication date: July 7, 2005
    Inventors: William Caldwell, Gary Dull, Balwinder Bhatti, Srishailkumar Hadimani, Haeil Park, Jared Wagner, Peter Crooks, Patrick Lippiello, Merouane Bencherif
  • Publication number: 20050131034
    Abstract: Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.
    Type: Application
    Filed: February 1, 2005
    Publication date: June 16, 2005
    Inventors: William Caldwell, Gary Dull, Balwinder Bhatti, Srishailkumar Hadimani, Haeil Park, Jared Wagner, Peter Crooks
  • Publication number: 20050032886
    Abstract: Compounds of the formula having anti-tumor activity, wherein R1 and R2 are as described herein.
    Type: Application
    Filed: July 9, 2004
    Publication date: February 10, 2005
    Inventors: Peter Crooks, Craig Jordan, Xiaochen Wei
  • Publication number: 20040266737
    Abstract: The present invention provides pharmaceutical preparations and the uses thereof for preventing and/or treating seizures and other electroconvulsive disorders by administering a pharmaceutically effective amount of a therapeutic compound having the following formula (I): 1
    Type: Application
    Filed: May 14, 2004
    Publication date: December 30, 2004
    Applicant: University of Kentucky
    Inventors: Peter A. Crooks, Aimee Karis Bence, David Robert Worthern
  • Publication number: 20040266824
    Abstract: The present invention is directed to 2,6-disubstituted piperidine and piperazine analogs having the following general formula: 1
    Type: Application
    Filed: March 31, 2004
    Publication date: December 30, 2004
    Inventors: Peter A. Crooks, Linda Dwoskin, Marlon D. Jones, Dennis Keith Miller, Seth Davin Norholm, Guangrong Zheng, Sairam Krishamurthy
  • Publication number: 20040248964
    Abstract: The present invention relates to norketamine and ketamine/norketamine prodrugs, and methods of their use as analgesics. More particularly, the invention relates to norketamine and N-conjugated prodrugs of ketamine and norketamine, and methods of using these agents for the management of chronic pain without requiring administration of narcotics. The invention relates to self-management of pain on an outpatient basis comprising administering via conventional routes, including transdermal, nasal, rectal, oral, transmucosal, intravenous, intramuscular, and other routes, one or more doses of norketamine and/or ketamine/norketamine prodrugs effective to alleviate pain to a subject suffering from pain. Uses of norketamine and ketamine/norketamine prodrugs would also apply, to treating headaches, drug abuse, mood and anxiety disorders, as well as other neuropsychiatric disorders, both motoric and cognitive, such as Alzheimer's disease, Parkinson's syndrome, which are thought to be caused by neurodegeneration.
    Type: Application
    Filed: November 18, 2003
    Publication date: December 9, 2004
    Inventors: Peter A. Crooks, Miguel Rivera
  • Publication number: 20040214784
    Abstract: The present invention relates to the field of prodrugs of chemotherapeutic agents and method of use thereof.
    Type: Application
    Filed: May 24, 2004
    Publication date: October 28, 2004
    Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Hong Guo, Paul Ashton
  • Patent number: 6765019
    Abstract: The present invention relates to the field of prodrugs of chemotherapeutic agents and method of use thereof.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: July 20, 2004
    Assignee: University of Kentucky Research Foundation
    Inventors: Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Hong Guo, Paul Ashton
  • Patent number: 6703406
    Abstract: Compounds used for treating dependence on or withdrawal from a drug of abuse, for an eating disorder or for a CNS disease or pathology having the following formulas:
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: March 9, 2004
    Assignee: University of Kentucky Research Foundation
    Inventors: Peter A. Crooks, Linda Dwoskin, Dennis Keith Miller, Vladimir P. Grinevich, Seth Davin Norrholm, Guangrong Zheng
  • Publication number: 20040019081
    Abstract: Compounds used for treating dependence on or withdrawal from a drug of abuse, for an eating disorder or for a CNS disease or pathology having the following formulas: 1
    Type: Application
    Filed: June 7, 2002
    Publication date: January 29, 2004
    Inventors: Peter A. Crooks, Linda Dwoskin, Dennis Keith Miller, Vladimir P. Grinevich, Seth Davin Norrholm, Guangrong Zheng
  • Publication number: 20030225142
    Abstract: Compounds for treating abuse of nicotinic receptor agonists, addiction to psychostimulant drugs, addiction to opiates, addiction to alcohol, addiction to tobacco products, addiction to nicotine, schizophrenia and related diseases, depression and related conditions, Alzheimer's disease, Parkinson's disease, irritable bowel syndrome, and colitis. The compounds competitively inhibit central nervous system acting nicotinic receptor agonists and act at the putative &agr;3&bgr;2* and &agr;4&bgr;2 neuronal nicotinic receptors in the central nervous system.
    Type: Application
    Filed: December 26, 2002
    Publication date: December 4, 2003
    Inventors: Peter A. Crooks, Linda Dwoshin, Rui Xu, Joshua T. Ayers
  • Publication number: 20030186942
    Abstract: The present invention provides pharmaceutical preparations and the uses thereof for preventing and/or treating seizures and other electroconvulsive disorders by administering a pharmaceutically effective amount of a therapeutic compound having the following formula (I): 1
    Type: Application
    Filed: January 16, 2003
    Publication date: October 2, 2003
    Inventors: Peter A. Crooks, Aimee Karis Bence, David Robert Worthern